Results for tag: "Large Molecule Injectable Drugs"

Within the pharmaceutical industry, Large Molecule Injectable Drugs, also known as biologics or biological drugs, are a category of medications that are typically derived from living organisms. These drugs are composed of sugars, proteins, nucleic acids, or a combination of these substances. They are produced through biotechnological methods and other cutting-edge technologies, such as recombinant DNA techniques, controlled gene expression, antibody technologies, and precise cell culture processes. Due to their complexity and macromolecular structure, large molecule injectables often require specialized delivery methods, such as injection or infusion, since they may be degraded if administered orally. The market for these drugs encompasses a range of therapeutic areas including oncology, immunology, and endocrinology, with treatments for conditions like diabetes, multiple sclerosis, rheumatoid arthritis, and various forms of cancer. Several key players in the market for Large Molecule Injectable Drugs include Roche, which has a strong portfolio in oncology and immunology; Amgen, known for its pioneering work in biotechnology; AbbVie, with celebrated entries in the fields of immunology and oncology; Pfizer, which has expanded its presence in biologics through research and acquisitions; and Merck, which continues to grow its biopharmaceutical division through innovation and strategic collaborations. These companies, among others, drive advancements within the sector by investing heavily in R&D and navigating complex regulatory landscapes to bring breakthrough therapies to market. Show Less Read more